Cargando…

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination

We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelbenegger, Georg, Cacioppo, Filippo, Firbas, Christa, Jilma, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472996/ https://www.ncbi.nlm.nih.gov/pubmed/34579193 http://dx.doi.org/10.3390/vaccines9090956

Ejemplares similares

Ad26.cov2-s: Rhabdomyolysis: case report
Publicado: (2021)

Defibrotide enhances fibrinolysis in human endotoxemia – a randomized, double blind, crossover trial in healthy volunteers
por: Schoergenhofer, Christian, et al.
Publicado: (2019)

Anticoagulant Treatment Regimens in Patients With Covid‐19: A Meta‐Analysis
por: Jorda, Anselm, et al.
Publicado: (2021)

The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial
por: Kovacevic, Katarina D., et al.
Publicado: (2021)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Severe rhabdomyolysis secondary to COVID-19 mRNA vaccine in a teenager
por: Pucchio, Aidan, et al.
Publicado: (2022)

High Titer Persistent Neutralizing Antibodies Induced by TSST-1 Variant Vaccine Against Toxic Shock Cytokine Storm
por: Roetzer, Andreas, et al.
Publicado: (2020)

Vaccine-induced pseudothrombocytopenia after Ad26.COV2.S vaccination
por: Kemper, Marcel, et al.
Publicado: (2021)

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
por: Ay, Cihan, et al.
Publicado: (2023)

Brain venography performance following the pause of Ad.26.COV2.S COVID-19 vaccine administration
por: Long, Clayton V., et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis
por: Jorda, Anselm, et al.
Publicado: (2022)

Surface cooling for induction of mild hypothermia in conscious healthy volunteers - a feasibility trial
por: Testori, Christoph, et al.
Publicado: (2011)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

Acute disseminated encephalomyelitis following the COVID-19 vaccine Ad26.COV2.S, a case report
por: Gustavsen, Stefan, et al.
Publicado: (2023)

Widespread annular eruption after Ad26.COV2.S COVID-19 vaccine
por: Song, Eingun James, et al.
Publicado: (2021)

Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male
por: Sutcu, Murat, et al.
Publicado: (2022)

Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
por: Sablerolles, Roos S G, et al.
Publicado: (2022)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19
por: Corchado-Garcia, Juan, et al.
Publicado: (2021)

Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination
por: Ujueta, Francisco, et al.
Publicado: (2021)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Rhabdomyolysis Secondary to COVID-19 Vaccination
por: Mack, Mariah, et al.
Publicado: (2021)

Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report
por: Naghashzadeh, Farah, et al.
Publicado: (2022)

A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine
por: Lospinoso, Kristen, et al.
Publicado: (2021)

Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine
por: Schmidt, Katja G., et al.
Publicado: (2023)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
por: Muir, Kate-Lynn, et al.
Publicado: (2021)

Rhabdomyolysis Caused by Rhinovirus
por: Tan, Lay Ong, et al.
Publicado: (2016)

Rhabdomyolysis or Myositis following a SARS-CoV-2 Vaccination
por: Finsterer, Josef, et al.
Publicado: (2023)

VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis
por: Kennedy, Vanessa E., et al.
Publicado: (2021)

A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination
por: Morehouse, Zachary P, et al.
Publicado: (2021)

Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
por: Mahrokhian, Shant H., et al.
Publicado: (2022)

Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event
Publicado: (2022)

Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations
por: Botton, Jérémie, et al.
Publicado: (2022)

Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system
por: Woo, Emily Jane, et al.
Publicado: (2022)

Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis
por: John, Binu V., et al.
Publicado: (2022)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Antigen specific T cells in people with obesity at five months following ChAdOx1 COVID-19 vaccination
por: Kelly, Neil E. Wrigley, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3q7i807s1k6dfpbtjql1d06d0p